Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- P/B of 28.30 — trading above book value
- Piotroski F-Score 2/9 — signs of financial weakness
- Loss-making — negative ROE of -178.8%
- Revenue growing at 15% annually
CAPSOVISION, INC. (CV) is a Healthcare company operating in Electromedical & Electrotherapeutic Apparatus, listed on the NASDAQ , with a market capitalisation of $375 million . Key value metrics: P/B ratio 28.30, Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
CAPSOVISION, INC. — Fundamental Analysis Summary
On financial health, CV shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and negative return on equity of -178.8% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.26.
StockPik's composite Value Score for CV is 25/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CV reports a solid gross margin of 55.1% (sector average: 33.5%) and a negative operating margin of -187.5%.
CV shows revenue growing at 15% year-over-year, with earnings declining at 27%.